Difference between revisions of "Global Template"
Jump to navigation
Jump to search
| [unchecked revision] | [unchecked revision] |
| (7 intermediate revisions by the same user not shown) | |||
| Line 2: | Line 2: | ||
==Primary Author(s)*== | ==Primary Author(s)*== | ||
| − | Put your text here | + | Put your text here (Example: Jane Smith, PhD, Institute of Genomics) |
__TOC__ | __TOC__ | ||
| Line 44: | Line 44: | ||
{| class="wikitable sortable" | {| class="wikitable sortable" | ||
|- | |- | ||
| − | ! Finding | + | !Finding!!Marker |
|- | |- | ||
| − | |Positive (universal) || EXAMPLE CD1 | + | |Positive (universal)||EXAMPLE CD1 |
|- | |- | ||
| − | |Positive (subset) || EXAMPLE CD2 | + | |Positive (subset)||EXAMPLE CD2 |
|- | |- | ||
| − | |Negative (universal) || EXAMPLE CD3 | + | |Negative (universal)||EXAMPLE CD3 |
|- | |- | ||
| − | |Negative (subset) || EXAMPLE CD4 | + | |Negative (subset)||EXAMPLE CD4 |
|} | |} | ||
| Line 61: | Line 61: | ||
{| class="wikitable sortable" | {| class="wikitable sortable" | ||
|- | |- | ||
| − | ! Chromosomal Rearrangement !! Genes in Fusion (5’ or 3’ Segments) !! Pathogenic Derivative !! Prevalence | + | !Chromosomal Rearrangement!!Genes in Fusion (5’ or 3’ Segments)!!Pathogenic Derivative!!Prevalence |
|- | |- | ||
| − | |EXAMPLE t(9;22)(q34;q11.2) || EXAMPLE 3'ABL1 / 5'BCR || EXAMPLE der(22) || EXAMPLE 5% | + | |EXAMPLE t(9;22)(q34;q11.2)||EXAMPLE 3'ABL1 / 5'BCR||EXAMPLE der(22)||EXAMPLE 5% |
|- | |- | ||
| − | |EXAMPLE t(8;21)(q22;q22) || EXAMPLE 5'RUNX1 / 3'RUNXT1 || EXAMPLE der(8) || EXAMPLE 5% | + | |EXAMPLE t(8;21)(q22;q22)||EXAMPLE 5'RUNX1 / 3'RUNXT1||EXAMPLE der(8)||EXAMPLE 5% |
|} | |} | ||
| Line 78: | Line 78: | ||
{| class="wikitable sortable" | {| class="wikitable sortable" | ||
|- | |- | ||
| − | ! Chromosome Number !! Gain/Loss/Amp/LOH !! Region | + | !Chromosome Number!!Gain/Loss/Amp/LOH!!Region |
|- | |- | ||
| − | |EXAMPLE 8 || EXAMPLE Gain || EXAMPLE chr8:0-1000000 | + | |EXAMPLE 8||EXAMPLE Gain||EXAMPLE chr8:0-1000000 |
|- | |- | ||
| − | |EXAMPLE 7 || EXAMPLE Loss || EXAMPLE chr7:0-1000000 | + | |EXAMPLE 7||EXAMPLE Loss||EXAMPLE chr7:0-1000000 |
|} | |} | ||
| Line 91: | Line 91: | ||
{| class="wikitable sortable" | {| class="wikitable sortable" | ||
|- | |- | ||
| − | ! Gene !! Mutation !! Oncogene/Tumor Suppressor/Other !! Presumed Mechanism (LOF/GOF/Other; Driver/Passenger) !! Prevalence (COSMIC/TCGA/Other) | + | !Gene!!Mutation!!Oncogene/Tumor Suppressor/Other!!Presumed Mechanism (LOF/GOF/Other; Driver/Passenger)!!Prevalence (COSMIC/TCGA/Other) |
|- | |- | ||
| − | | EXAMPLE TP53 || EXAMPLE R273H || EXAMPLE Tumor Suppressor || EXAMPLE LOF || EXAMPLE 20% | + | |EXAMPLE TP53||EXAMPLE R273H||EXAMPLE Tumor Suppressor||EXAMPLE LOF||EXAMPLE 20% |
|} | |} | ||
| Line 99: | Line 99: | ||
{| class="wikitable sortable" | {| class="wikitable sortable" | ||
|- | |- | ||
| − | ! Type !! Gene/Region/Other | + | !Type!!Gene/Region/Other |
|- | |- | ||
| − | | Concomitant Mutations || EXAMPLE IDH1 R123H | + | |Concomitant Mutations||EXAMPLE IDH1 R123H |
|- | |- | ||
| − | | Secondary Mutations || EXAMPLE Trisomy 7 | + | |Secondary Mutations||EXAMPLE Trisomy 7 |
|- | |- | ||
| − | |Mutually Exclusive || EXAMPLE EGFR Amplification | + | |Mutually Exclusive||EXAMPLE EGFR Amplification |
|} | |} | ||
| Line 122: | Line 122: | ||
==Clinical Significance (Diagnosis, Prognosis and Therapeutic Implications)== | ==Clinical Significance (Diagnosis, Prognosis and Therapeutic Implications)== | ||
| − | Put your text here | + | Diagnosis: Put your text here |
| + | |||
| + | Prognosis: Put your text here | ||
| + | |||
| + | Therapeutic: Put your text here | ||
==Familial Forms== | ==Familial Forms== | ||
| Line 134: | Line 138: | ||
==Links== | ==Links== | ||
| − | Put your links here | + | Put your links here (use "Link" icon at top of page) |
==References== | ==References== | ||
| + | (use "Cite" icon at top of page) | ||
| + | <references /> | ||
| + | ===EXAMPLE Book=== | ||
| − | + | #Arber DA, et al., (2017). Acute myeloid leukaemia with recurrent genetic abnormalities, in World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4th edition. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Arber DA, Hasserjian RP, Le Beau MM, Orazi A, and Siebert R, Editors. IARC Press: Lyon, France, p129-171. | |
| − | #Arber DA, et al., ( | ||
| − | |||
| − | |||
| − | |||
| − | == Notes == | + | ==Notes== |
<nowiki>*</nowiki>Primary authors will typically be those that initially create and complete the content of a page. If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the CCGA coordinators (contact information provided on the homepage). Additional global feedback or concerns are also welcome. | <nowiki>*</nowiki>Primary authors will typically be those that initially create and complete the content of a page. If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the CCGA coordinators (contact information provided on the homepage). Additional global feedback or concerns are also welcome. | ||
Latest revision as of 08:41, 15 April 2021
 | This page is under construction |
Primary Author(s)*
Put your text here (Example: Jane Smith, PhD, Institute of Genomics)
Cancer Category/Type
Put your text here
Cancer Sub-Classification / Subtype
Put your text here
Definition / Description of Disease
Put your text here
Synonyms / Terminology
Put your text here
Epidemiology / Prevalence
Put your text here
Clinical Features
Put your text here
Sites of Involvement
Put your text here
Morphologic Features
Put your text here
Immunophenotype
Put your text here and/or fill in the table
| Finding | Marker |
|---|---|
| Positive (universal) | EXAMPLE CD1 |
| Positive (subset) | EXAMPLE CD2 |
| Negative (universal) | EXAMPLE CD3 |
| Negative (subset) | EXAMPLE CD4 |
Chromosomal Rearrangements (Gene Fusions)
Put your text here and/or fill in the table
| Chromosomal Rearrangement | Genes in Fusion (5’ or 3’ Segments) | Pathogenic Derivative | Prevalence |
|---|---|---|---|
| EXAMPLE t(9;22)(q34;q11.2) | EXAMPLE 3'ABL1 / 5'BCR | EXAMPLE der(22) | EXAMPLE 5% |
| EXAMPLE t(8;21)(q22;q22) | EXAMPLE 5'RUNX1 / 3'RUNXT1 | EXAMPLE der(8) | EXAMPLE 5% |
Characteristic Chromosomal Aberrations / Patterns
Put your text here
Genomic Gain/Loss/LOH
Put your text here and/or fill in the table
| Chromosome Number | Gain/Loss/Amp/LOH | Region |
|---|---|---|
| EXAMPLE 8 | EXAMPLE Gain | EXAMPLE chr8:0-1000000 |
| EXAMPLE 7 | EXAMPLE Loss | EXAMPLE chr7:0-1000000 |
Gene Mutations (SNV/INDEL)
Put your text here and/or fill in the tables
| Gene | Mutation | Oncogene/Tumor Suppressor/Other | Presumed Mechanism (LOF/GOF/Other; Driver/Passenger) | Prevalence (COSMIC/TCGA/Other) |
|---|---|---|---|---|
| EXAMPLE TP53 | EXAMPLE R273H | EXAMPLE Tumor Suppressor | EXAMPLE LOF | EXAMPLE 20% |
Other Mutations
| Type | Gene/Region/Other |
|---|---|
| Concomitant Mutations | EXAMPLE IDH1 R123H |
| Secondary Mutations | EXAMPLE Trisomy 7 |
| Mutually Exclusive | EXAMPLE EGFR Amplification |
Epigenomics (Methylation)
Put your text here
Genes and Main Pathways Involved
Put your text here
Diagnostic Testing Methods
Put your text here
Clinical Significance (Diagnosis, Prognosis and Therapeutic Implications)
Diagnosis: Put your text here
Prognosis: Put your text here
Therapeutic: Put your text here
Familial Forms
Put your text here
Other Information
Put your text here
Links
Put your links here (use "Link" icon at top of page)
References
(use "Cite" icon at top of page)
EXAMPLE Book
- Arber DA, et al., (2017). Acute myeloid leukaemia with recurrent genetic abnormalities, in World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4th edition. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Arber DA, Hasserjian RP, Le Beau MM, Orazi A, and Siebert R, Editors. IARC Press: Lyon, France, p129-171.
Notes
*Primary authors will typically be those that initially create and complete the content of a page. If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the CCGA coordinators (contact information provided on the homepage). Additional global feedback or concerns are also welcome.